The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.
A 36-year-old man restarted hair loss treatment after a break, using topical Minoxidil 5% twice daily, topical Finasteride 0.01% daily, and Ketoconazole 2% three times a week, along with supplements like Vitamin B12, D3, C, Biotin, Omega-3, zinc, and copper. He avoids oral Finasteride due to side effects and plans to evaluate progress after a year.
The user is experiencing hair loss and has been using RU58841 but is considering pyrilutamide and minoxidil, avoiding finasteride due to side effects. Another user suggests finasteride or dutasteride as essential, possibly in topical form, while dismissing saw palmetto as ineffective.
A 27-year-old shared a 90-day hair loss treatment update using Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and microneedling, reporting positive results with improved hairline and density. They experienced minor side effects and noted a decrease in hair shedding.
The user has been using topical Minoxidil (5%) and finasteride (0.1%) twice daily for 2 months, with occasional missed applications. They also use a zinc pyrithione shampoo every 2 days and do not dermaroll.
A 22-year-old resumed using finasteride, minoxidil, and a 0.5mm dermaroller after stopping for two years, experiencing positive results and improved mood. The discussion includes debates on the effects of finasteride on neurosteroids and the optimal dermaroller needle length for hair regrowth.
The user is currently using alfatradiol and fluridil for hair loss and is considering adding low-dose topical finasteride but is concerned about potential side effects due to past mental health issues. They are seeking others' experiences with these treatments and their effectiveness.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.